Online inquiry

IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11357MR)

This product GTTS-WQ11357MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Neuromyelitis optica (NMO) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ11357MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12541MR IVTScrip™ mRNA-Anti-Canlupfam NGF, NV-01(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA NV-01
GTTS-WQ12039MR IVTScrip™ mRNA-Anti-NRP1, MNRP1685A(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MNRP1685A
GTTS-WQ7078MR IVTScrip™ mRNA-Anti-FAP, FAP-IL2v(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA FAP-IL2v
GTTS-WQ8800MR IVTScrip™ mRNA-Anti-PDCD1, IBI-308(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA IBI-308
GTTS-WQ6428MR IVTScrip™ mRNA-Anti-HA, CT-P22(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CT-P22
GTTS-WQ13946MR IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA REGN-2810
GTTS-WQ13026MR IVTScrip™ mRNA-Anti-IFNAR, Peg-IFNA2 R23(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Peg-IFNA2 R23
GTTS-WQ12825MR IVTScrip™ mRNA-Anti-MASP2, OMS721(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA OMS721
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW